C07D 239/02
Not condensed with other rings
Official title: not condensed with other rings
C07D239/02 (Not condensed with other rings) appears on 9,129 US grants and 7,689 published applications in this corpus.
Search patents in C07D- Granted patents
- 9,129
- Published applications
- 7,689
- Assignees
- 2,753
- Inventors
- 22,401
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 107 | 0 |
| 1977 | 82 | 0 |
| 1978 | 82 | 0 |
| 1979 | 73 | 0 |
| 1980 | 90 | 0 |
| 1981 | 102 | 0 |
| 1982 | 81 | 0 |
| 1983 | 83 | 0 |
| 1984 | 96 | 0 |
| 1985 | 128 | 0 |
| 1986 | 127 | 0 |
| 1987 | 128 | 0 |
| 1988 | 128 | 0 |
| 1989 | 146 | 0 |
| 1990 | 161 | 0 |
| 1991 | 150 | 0 |
| 1992 | 160 | 0 |
| 1993 | 176 | 0 |
| 1994 | 175 | 0 |
| 1995 | 174 | 0 |
| 1996 | 159 | 0 |
| 1997 | 202 | 0 |
| 1998 | 206 | 0 |
| 1999 | 180 | 0 |
| 2000 | 169 | 0 |
| 2001 | 201 | 36 |
| 2002 | 222 | 205 |
| 2003 | 185 | 291 |
| 2004 | 175 | 342 |
| 2005 | 146 | 332 |
| 2006 | 198 | 301 |
| 2007 | 163 | 288 |
| 2008 | 157 | 309 |
| 2009 | 199 | 345 |
| 2010 | 231 | 384 |
| 2011 | 215 | 336 |
| 2012 | 279 | 322 |
| 2013 | 309 | 326 |
| 2014 | 329 | 380 |
| 2015 | 352 | 403 |
| 2016 | 294 | 366 |
| 2017 | 343 | 377 |
| 2018 | 289 | 309 |
| 2019 | 259 | 285 |
| 2020 | 254 | 314 |
| 2021 | 183 | 293 |
| 2022 | 211 | 274 |
| 2023 | 158 | 293 |
| 2024 | 160 | 249 |
| 2025 | 149 | 183 |
| 2026 | 103 | 146 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07D 239/24Having three or more double bonds between ring members or between ring8,336
- C07D 239/06Having one double bond between ring members or between a ring member579
- C07D 239/20Having two double bonds between ring members or between ring members and361
- C07D 239/04Having no double bonds between ring members or between ring members and116
Recent patents
- Crystalline forms of a BTK inhibitor6 Oct 2026US 12,751,949 B2Novartis AG
- Diaminopyrimidine carboxamide inhibitors of HPK16 Oct 2026US 12,753,163 B2Merck Sharp & Dohme Corp.
- P38alpha mitogen-activated protein kinase inhibitors6 Oct 2026US 12,753,184 B2Gen1E Lifesciences Inc.
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Probenecid compounds for the treatment of inflammasome-mediated lung disease8 Oct 2026US 2026/0308131 A1Bacainn Biotherapeutics, Ltd.
- Estrogen-receptor modulator and use thereof8 Oct 2026US 2026/0308139 A1Jiangsu Vcare PharmaTech Co., Ltd.
- Neuroactive androgen receptor modulators and use thereof1 Oct 2026US 2026/0294908 A1ENDOCHEM PHARMACEUTICALS (BEIJING) CO., LTD. Beijing
- An organic compound and an organic electroluminescent device using the same1 Oct 2026US 2026/0297034 A1Solus Advanced Materials Co., Ltd.
- Inhibitors of spinster homolog 2 (spns2) for use in therapy1 Oct 2026US 2026/0297044 A1University of Virginia Patent Foundation
Most cited
By later US patents
- Pyrimidine, cyanoguanidines as K-channel blockers1,019US 5,633,374 AThe Upjohn Company · 1997
- Pyrimidine derivatives for labeled binding partners639US 5,502,177 AGilead Sciences, Inc. · 1996
- Pyrimidine derivatives488US 6,005,096 AGilead Sciences, Inc. · 1999
- Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates468US 5,700,920 ANovartis AG · 1997
- Pyrimidine derivatives for labeled binding partners456US 5,763,588 AGilead Sciences, Inc. · 1998